Thirteen chemical compounds belonging to the fused heterocyclic pyrimidines were synthesized and screened in order to assay their antiviral activity against the avian influenza virus (H5N1) A/Chicken/Qalubiya/1/2006(H5N1) by plaque reduction assay on MDCK cells. All tested compounds were non-toxic on the cells. Ten out of thirteen compounds (10, 13, 9, 12, 1, 11, 7, 8, 3 and 4) showed moderate percentage of inhibition respectively at concentration 20 μg/ml while the remaining three compounds (5, 2 and 6) showed weak inhibitory activity respectively at same concentration.
INTRODUCTION
Avian influenza A/H5N1 presents one of the major hazards to the mankind in the 21 st century. Influenza virus A/H5N1 possesses a number of characteristics of the ideal future pandemic pathogen such as the following: the potential for the infection of the greatest number of animal species (compared to other known influenza strains), high mortality rate (30-70%) as well as the continuous evolution towards the increase of virulence, the ability for human transmission and the resistance to the existing therapeutic agents. World Health Organization (WHO) has identified avian influenza A/H5N1 as a disease with pandemic potential, which represents a health risk to the world population as a whole (Tapper, 2006) . Periodically, completely novel antigenic subtypes of influenza viruses have been introduced in the human population, causing large-scale global outbreaks with high death tolls (Basler and Aguilar, 2008) . Although vaccination provides the primary protection against influenza virus infections but the continuous and unpredictable antigenic variation in the influenza viruses has made vaccine strains relatively or totally ineffective beside they must be selected annually. Therefore, vaccine production may not satisfy the need during an influenza pandemic (Gong et al., 2007) . The use of antiviral drugs against influenza virus could therefore represent a first line of defense against a new pandemic, allowing the control of the infection until sufficient quantities of a suitable vaccine can be produced (Sugrue et al., 2008) . Two classes of these antiviral drugs, adamantanes and neuraminidase (NA) inhibitors, are currently prescribed for the prophylaxis and treatment of influenza infections (Hsieh and Hsu, 2007) . Adamantanes (amantadine and rimantadine) target the proton channel formed by the viral M2 protein whereas two NA inhibitors, orally bioavailable oseltamivir and inhaled zanamivir, are the only drugs currently recommended for the 26 treatment of influenza virus infection. These drugs have been proven to be useful for reducing clinical symptoms, but their utility has been limited by side effects and high rate of emergence of resistant viral strains (Gubareva et al., 1998; Kiso et al., 2004 and Le et al., 2005) . Therefore the need for identifying new alternative antiinfluenza drugs becomes a matter of certainty and an urgent global need in the face of new pandemic strains. The objective of this study was to identify novel anti-influenza virus using heterocyclic pyrimidine compounds because an interest is aroused to the biologically active pyrimidine and fused heterocyclic pyrimidine nucleosides as potent antiviral agents (Cristescu and Czobor, 1998; Rashad and Ali, 2006) . O (304.31): required C, 63.15; H, 3.97; N, 27.62; found C, 63.20; H, 4.05; N, 27.48 . Compound number two: 5-Amino-1-(6-ptolyl-pyridazin-3-yl)-1H-pyrazole-4-carboxylic acid amide was prepared by Shamroukh et al., (2005 Rashad et al., (2009 
MATERIALS AND METHODS
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Cell culture propagation:
The MDCK cells were grown to confluence in complete growth medium in 75 cm 2 culture flasks (Greiner bioone GmbH, Germany). The medium was discarded and then cells were treated with trypsin-versene for dissociation of the cell monolayer. Cells were incubated for 0.5-5 min at 37ºC and detachment of the cells was carefully observed. Cells were spun down at 2500 g for 2 min, resuspended in 1 ml complete medium. The exact cell count and viability was recorded by mixing a 50 μl aliquot of the cells with equal volume of trypan blue (5 gm/L; BiochromKG, Berlin, Germany) using a hemocytometer (Right Line; Sigma, Deisenhofen, Germany). According to the recorded count certain volume of the resuspended cells was used to prepare fresh cultures in plates or flasks.
Viral titer determination by plaque assay:
Monolayer MDCK cells (6 × 10 5 cells/well) were washed once with Dulbecco's phosphatebuffered saline (DPBS), and infected with a serially diluted viral suspension. After adsorption for 1 h at 37°C, the viral suspension was replaced with over layer medium, (DMEM with penicillin [100 U/mL], streptomycin [100 μg/mL], L-glutamine [2 mM], and nonessential amino acid mixture [0.1 mM]) containing 2.5 μg/mL trypsin and 0.3 % agarose). After incubation for 2-3 days at 37°C under 5 % CO 2 , the cells were fixed with 10 % formaldehyde and then stained with 1 % crystal violet. The titer of the virus was expressed in plaque-forming units (PFU) per milliliter. Preparation of synthetic compounds for bioassay: Tested compounds were dissolved as 10 mg each in 1 ml of 10 % Dimethyl Sulfoxide (DMSO) in deionized water (900 µL de-ionized water and 100 µL DMSO). Decontamination was carried out by adding 1 % antibiotic-antimycotic mixture (10,000 U penicillin G sodium, 10,000 μg streptomycin sulfate, and 250 μg amphotericin B, PAA Laboratories GmbH, Austria) and the compounds were incubated at 37ºC for 30 min then stored at -20ºC. Sterility test was performed out in nutrient agar to ensure the sterility of the prepared compounds. Cytotoxicity Assay: Cell toxicity was carried out to determine the cell culture safe doses of the dissolved compounds and performed by Cell morphology technique (Aquino et al., 1989) which was made in 96 well plates: In order to determine the safe dose of the tested compounds that doesn't harm the (MDCK) cells, different concentrations from each compound ranging from 10 to 100 µg / ml were applied to cells. Each concentration was tested for cytotoxicity by observing any morphologically changes in the cultured cells microscopically after 24 hours incubation. Antiviral Screening: Plaque reduction assay is the most widely accepted method for determining the % inhibition of virus as a result of being subjected to a given material (Tebas et al., 1995) . A 12 well plate was cultivated with the MDCK cells (10 5 cell/ml) and incubated for 24 hours at 37ºC. Virus was diluted to give 10 3 PFU/ml final concentration and mixed with the safe concentrations of each compound as mentioned previously and incubated for 1 hour at 37ºC. Growth medium was removed from the multi-well plate and virus-compound mixture was inoculated in each well. After 1 hour contact time at 37ºC for virus adsorption, the inoculum was aspirated and 1 ml of cell-specific 2x medium 2 % agarose was overlayed the cell sheet. The plates were left to solidify at room temperature and incubated for 2-3 days at 37ºC until the development of the viral plaques. Formalin was added for two hours for fixation then plates were stained with crystal violet staining solution. Control virus and cells were treated identically without addition of compounds. Viral plaques were counted and the percentage of virus reduction was calculated through the following equation: % inhibition = viral count (untreated) -viral count (treated)/ viral count (untreated) x 100.
RESULTS AND DISCUSSION
The result in Fig. 1 showed that the dilution 10 -3 of H5N1 virus was the most suitable dilution which gave 80 -100 PFU/ml. So, this dilution (10 -3 of virus) will be applied in subsequent experiments. Also the results of cytotoxicity test indicated that all tested concentrations starting from 10 to 100 µg/ml for each compound were safe on MDCK cells and didn't show any toxicity on MDCK cells. The lowest concentrations 10 & 20 µg/ml for each compound was preferably chosen to be used in plaque reduction assay since the commercially available anti-H5N1 therapeutic agents are effective at low concentration. This result agreed with several searches in that field for example, toxicity test using neutral red dye uptake method (Smee et. al, 2002) , using 0.011 % final concentration of the dye for 2 h for the compound 4-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene) amino]-N-(4,6-dimethyl-2-pyrimidin-2-yl)benzenesulphonamide and its derivatives showed that no toxicity was apparent to the uninfected stationary MDCK cell monolayers at the highest (100 μg/ml) concentration (Selvam et al., 2006) . A series of pyrazinecarboxamide derivatives were found to inhibits the influenza viral RNAdependent RNA polymerase without cytotoxicity to mammalian cells (Furuta et. al, 2009 ). The cytotoxicity test using MTT assay (Mossman, 1983) for some novel fused thiophene and thienopyrimidine derivatives showed that they were safe on MDCK cells (Rashad et. al, 2010) . However, the acyclic nucleosides in the 5-alkynyl-and 6-alkylfuro [2, 3-d] pyrimidine series showed cellular toxicity against PBM, CEM and VERO cells, probably by inhibiting cell DNA synthesis (Amblard et. al, 2005) .
Plaque reduction assay was applied to get the percentage of virus inhibition as a result of treatment with certain compound. The results in Table 1 showed that 10 out of 13 compounds showed moderate percentage of inhibition at concentration 20 µg/ml. These compounds were number 10, 13, 9, 12, 1, 11, 7, 8, 3 and 4 giving 66.6, 66.6, 60.0, 60.0, 58.3, 55.0, 53.3, 53.3, 50 .0 and 50.0 % of inhibition, respectively. The remaining 3 compounds showed weak inhibitory activity at same concentration. These compounds were number 5, 2 and 6 giving 35, 33.3 and 33.3 % of inhibition, respectively. Generally, at conc. 10 µg/ml the percentage inhibition was slightly reduced for most tested compounds comparing with 20 µg/ml but this reduction was non significance. Several reports also have been demonstrated the effectiveness of synthetic fused heterocyclic pyrimidine compounds in inhibiting influenza viruses. For examples, The 4-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene) amino]-N-(4,6-dimethyl-2-pyrimidin-2-yl) benzenesulphonamide and its derivatives showed antiviral potencies (90 % inhibition) against influenza A (H1N1, H3N2, and H5N1) and B viruses in MDCK cell culture (Selvam et al., 2006) . The novel 4-(4-((3-(2-amino-4-hydroxy-6-methyl-5-pyrimidinyl) propyl) amino) phenyl)-1-chloro-3-buten-2-one showed the ability to inhibit the avian influenza H5N1 virus (lee et al., 2009 (Rashad et al., 2010) . Pyrazole compound BPR1P0034 showed potent and selective anti-influenza virus activity (Shih et al., 2010) . However, some newly synthesized indenothienopyrimidine derivatives didn't show any antiviral activity against H5N1 virus (Shamrokh et al., 2010 ) also the novel 4-Amino-2-(benzylthio) -6-(4-methoxyphenyl) pyrimidine -5-carbonitrile didn't possess any antiviral activity against H5N1 virus (Mahmoud et al., 2011) while the antiviral activity of the novel acyclic nucleosides in the 5-alkynyland 6-alkylfuro [2, 3-d] pyrimidine series against H5N1 virus were secondary to their toxic effects on MDCK cell culture (Amblard et al., 2005) .
